Young-Jin Kim Biography and Net Worth

Director of Rezolute

Mr. Kim is Chairman & CEO of Handok Inc., one of the leading pharmaceutical companies in the Republic of Korea. Mr. Kim also serves on the Board of Directors of Genexine Inc.

Mr. Kim joined Handok Inc. in 1984 and spent two years between 1984 and 1986 working at Hoechst AG in Frankfurt, Germany. Between 1991 and 2005, he served as CEO of Roussel Korea, Hoechst Marion Roussel Korea, and Aventis Pharma Korea, and was also appointed as the Country Manager of Hoechst AG and Aventis in Korea between 1996 and 2005. In 1996, he was appointed as CEO of Handok. Mr. Kim has been serving as President of Handok Jeseok Foundation since 2014. He also has been serving as President of KDG (Korean-German Society) since 2010. Mr. Kim received an M.B.A. at the Kelley School of Business at Indiana University in 1984 and received the award of Distinguished Alumni Fellows from Indiana University. Mr. Kim completed the Advanced Management Program at the Harvard Business School in 1996.

What is Young-Jin Kim's net worth?: The estimated net worth of Young-Jin Kim is at least $81.71 million as of June 13th, 2025. Kim owns 8,423,386 shares of Rezolute stock worth more than $81,706,844 as of December 5th. This net worth evaluation does not reflect any other assets that Kim may own. Learn More about Young-Jin Kim's net worth.
How do I contact Young-Jin Kim?: The corporate mailing address for Kim and other Rezolute executives is 201 REDWOOD SHORES PARKWAY SUITE 315, REDWOOD CITY CA, 94065. Rezolute can also be reached via phone at (650) 206-4507 and via email at [email protected]. Learn More on Young-Jin Kim's contact information.
Has Young-Jin Kim been buying or selling shares of Rezolute?: Young-Jin Kim has not been actively trading shares of Rezolute within the last three months. Most recently, on Friday, June 13th, Young-Jin Kim bought 1,230,769 shares of Rezolute stock. The stock was acquired at an average cost of $3.25 per share, with a total value of $3,999,999.25. Following the completion of the transaction, the director now directly owns 8,423,386 shares of the company's stock, valued at $27,376,004.50. Learn More on Young-Jin Kim's trading history.
Who are Rezolute's active insiders?: Rezolute's insider roster includes Nevan Elam (CEO), Nevan Elam (Chief Executive Officer & Founder), Daron Evans (CFO), Wladimir Hogenhuis (Director), Wladimir Hogenhuis (Director), Young-Jin Kim (Director), Nerissa Kreher (Director), and Brian Roberts (Insider). Learn More on Rezolute's active insiders.
Are insiders buying or selling shares of Rezolute?: During the last twelve months, Rezolute insiders bought shares 10 times. They purchased a total of 1,299,405 shares worth more than $4,256,190.31. The most recent insider tranaction occured on June, 25th when insider Brian Kenneth Roberts bought 2,500 shares worth more than $10,950.00. Insiders at Rezolute own 14.8% of the company. Learn More about insider trades at Rezolute.
Information on this page was last updated on 6/25/2025.

Young-Jin Kim Insider Trading History at Rezolute

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/13/2025	Buy	1,230,769	$3.25	$3,999,999.25	8,423,386
3/7/2024	Buy	36,503	$1.91	$69,720.73	115,450

Young-Jin Kim Buying and Selling Activity at Rezolute

Rezolute Company Overview

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Today's Range

Now: $9.70

$9.28

$9.85

50 Day Range

MA: $9.37

$8.07

$10.76

2 Week Range

Now: $9.70

$2.21

$11.46

Volume

2,362,645 shs

Average Volume

1,471,023 shs

Market Capitalization

$899.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21